Senior Director
ITF Therapeutics
Senior Director
ITF Therapeutics
Develops and commercializes rare-disease therapies
About This Role:
The Sr. Director, Medical Affairs, Inherited Neurometabolic Disorders (IMD) is responsible for leading the U.S. Medical Affairs strategy for ITF Therapeutics' rare neurometabolic disease portfolio. Reporting to the Vice President of Medical Affairs & Patient Advocacy, this role serves as the senior U.S. medical leader for the neurometabolic therapeutics portfolio, ensuring effective translation of global medical strategy into impactful U.S. plans and successful launch execution.
As a member of the US Medical Affairs leadership team, the Senior Director provides strategic and scientific leadership across product development and commercialization, with responsibility for U.S. medical strategy, launch readiness, scientific engagement, field medical effectiveness, medical communications, education, payer engagement, and cross-functional execution.
Working closely with the Global Medical Director, this individual serves as the primary U.S. medical voice for the neurometabolic portfolio, ensuring global evidence generation, scientific communications, and medical activities address the needs of U.S. patients, healthcare professionals, payers, and other stakeholders.
The successful candidate will bring deep rare disease expertise, strong scientific and strategic leadership, and the ability to influence within a matrixed global organization. This leader will foster scientific excellence, collaboration, patient centricity, and innovation while helping establish ITF Therapeutics as a trusted partner within the neurometabolic community.
What You'll Do:
U.S. Medical Strategy & Leadership
Medical Launch Excellence
Scientific Communications, Evidence Generation & Insights
External Engagement & Market Access
Cross-Functional & Global Collaboration
Team Leadership & Organizational Development
Required Skills:
Preferred Skills:
Additional Information:
The base compensation range for this role is: $290,000 - $320,000. Compensation is determined through an analytical approach utilizing a combination of factors including, but not limited to, relevant skills & experience, job location, and internal equity.
Develops and commercializes rare-disease therapies
ITF Therapeutics is a division of Italfarmaco S.p.A. focused on developing and commercializing treatments for rare diseases in the U.S., especially Duchenne Muscular Dystrophy (DMD). The company works on early-stage research and clinical development, partnering with patient advocacy groups and clinical leaders to align programs with patient needs. Its lead program is DUVYZAT (givinostat), a histone deacetylase (HDAC) inhibitor aimed at DMD. Revenue comes from bringing these specialized therapies to market. Compared with competitors, ITF Therapeutics emphasizes collaboration with patient groups and clinicians, a pipeline-focused early-development approach, and a specialty in HDAC inhibitors for rare diseases. The company’s goal is to deliver effective treatments for rare-disease patients by advancing promising therapies through development and into commercialization.
Explore more opportunities at ITF Therapeutics